MTPVY yields 10.16% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 10
Combined, MTPVY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MTPVY + PFE for your $10,000?
Métropole Télévision S.A. provides a range of programs, products, and services on various media. It operates through four segments: Television, Radio, Production and Audiovisual Rights, and Diversification. The company operates free-to-air channels, including M6, W9, 6TER, and Gulli; pay channels, such as Paris Première, Téva, sérieclub, Canal J, Tiji, M6 Music, MCM, MCM Top, and RFM TV; on-demand televisions comprising 6play, Gulli Max, and Gulli Replay; and advertising agency, as well as produces news magazines comprising Capital, Zone Interdite, Enquête Exclusive, 66 Minutes, and Enquêtes criminelles for W9. It also operates radio stations that include RTL, RTL2, and Fun Radio; distributes audiovisual film rights; and produces and co-produces films. In addition, the company engages in the TV channel broadcasting business; production, co-production, or co-distribution of short and long-playing formats, which comprise singles and albums, as well as compilations on physical and digital formats; and events and shows, including concerts, stand-up comedians, music shows, exhibitions, etc. Further, it engages in the program production, digital production and publishing, merchandising rights exploitation, estate agency, animated feature films production, Internet content and access provision, print publications, and teleshopping program activities. It also provides training and wholesale trade services; sells house; and develops cinematographic works. Métropole Télévision S.A. was incorporated in 1986 and is headquartered in Neuilly-sur-Seine, France.
Full MTPVY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.